Vital KSK Holdings, Inc.
Fiscal Year Ending March 2026 Q3 Financial Summary [Japanese GAAP] (Consolidated)
For the third quarter of the fiscal year ending March 2026, net sales were 464,554 million yen (0.8% increase YoY), operating income was 3,119 million yen (42.3% decrease YoY), and net income attributable to owners of the parent for the quarter was 5,889 million yen (8.8% decrease YoY).
Key Figures
- Net Sales: 464,554 million yen (0.8% increase YoY)
- Operating Income: 3,119 million yen (42.3% decrease YoY)
- Net Income Attributable to Owners of Parent for the Quarter: 5,889 million yen (8.8% decrease YoY)
AI要約
Performance Overview
For the cumulative consolidated period of the third quarter of the fiscal year ending March 2026, net sales reached 464,554 million yen (0.8% increase YoY), operating income was 3,119 million yen (42.3% decrease YoY), and net income attributable to owners of the parent for the quarter was 5,889 million yen (8.8% decrease YoY). Core operating income before R&D expenses in the pharmaceutical business, a new business segment, was 4,002 million yen (74.0% compared to operating income YoY). Ordinary income was 6,692 million yen (4.2% increase YoY). By segment, the pharmaceutical wholesale business recorded net sales of 436,971 million yen (100.6% YoY) and operating income of 3,816 million yen (75.2% YoY). The pharmacy business reported net sales of 14,975 million yen (102.0% YoY) and operating income of 187 million yen (109.1% YoY). The animal pharmaceutical wholesale business had net sales of 9,488 million yen (108.2% YoY) and operating income of 221 million yen (91.1% YoY). The pharmaceutical business is a new segment with no recorded sales and a segment loss of 895 million yen. The nursing care rental and other businesses achieved net sales of 3,118 million yen (101.5% YoY) with an operating loss of 146 million yen.
Financial Position and Dividend Status
As of the third quarter of the fiscal year ending March 2026, total assets stood at 344,402 million yen, net assets at 111,437 million yen, and the equity ratio was 31.9%. The number of outstanding shares was 51,902,976 shares, with treasury stock amounting to 3,525,889 shares. The dividend was 34 yen per share at the end of the second quarter for fiscal 2026, with a year-end forecast of 34 yen, totaling an annual dividend forecast of 68 yen, representing an increase from the previous year's actual dividend of 45 yen. The company intends to continue promoting capital cost-conscious management under its medium-term management plan while focusing on growth investments and strengthening profitability.
